PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.28%
Revenue growth under 50% of MCHP's 5.63%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
0.54%
Gross profit growth under 50% of MCHP's 6.39%. Michael Burry would be concerned about a severe competitive disadvantage.
10.98%
EBIT growth 75-90% of MCHP's 13.15%. Bill Ackman would push for cost reforms or better product mix to narrow the gap.
10.98%
Operating income growth at 75-90% of MCHP's 13.15%. Bill Ackman would demand a plan to enhance operating leverage.
27.66%
Net income growth above 1.5x MCHP's 13.13%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
32.00%
EPS growth above 1.5x MCHP's 11.11%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
28.00%
Diluted EPS growth above 1.5x MCHP's 11.76%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-1.93%
Share reduction while MCHP is at 1.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.28%
Reduced diluted shares while MCHP is at 1.30%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.79%
Dividend reduction while MCHP stands at 25.26%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
86.17%
OCF growth above 1.5x MCHP's 33.08%. David Dodd would confirm a clear edge in underlying cash generation.
308.00%
FCF growth above 1.5x MCHP's 27.05%. David Dodd would verify if the firm’s strategic investments yield superior returns.
7.93%
10Y revenue/share CAGR under 50% of MCHP's 297.39%. Michael Burry would suspect a lasting competitive disadvantage.
32.39%
5Y revenue/share CAGR at 50-75% of MCHP's 53.46%. Martin Whitman would worry about a lagging mid-term growth trajectory.
69.82%
Positive 3Y CAGR while MCHP is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
102.84%
10Y OCF/share CAGR under 50% of MCHP's 714.74%. Michael Burry would worry about a persistent underperformance in cash creation.
72.68%
Below 50% of MCHP's 325.68%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
172.49%
Positive 3Y OCF/share CAGR while MCHP is negative. John Neff might see a big short-term edge in operational efficiency.
158.75%
Below 50% of MCHP's 491.23%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
36.06%
Below 50% of MCHP's 97.58%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
564.91%
Positive short-term CAGR while MCHP is negative. John Neff would see a clear advantage in near-term profit trajectory.
285.05%
Below 50% of MCHP's 1301.70%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
58.13%
Below 50% of MCHP's 223.46%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
7.89%
Below 50% of MCHP's 56.51%. Michael Burry suspects a serious short-term disadvantage in building book value.
39.88%
Dividend/share CAGR of 39.88% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
5.99%
Dividend/share CAGR of 5.99% while MCHP is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
-6.00%
Negative near-term dividend growth while MCHP invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
1.81%
AR growth well above MCHP's 1.53%. Michael Burry fears inflated revenue or higher default risk in the near future.
5.53%
We show growth while MCHP is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
0.54%
Asset growth well under 50% of MCHP's 5.98%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
5.72%
1.25-1.5x MCHP's 4.58%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-51.52%
We’re deleveraging while MCHP stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-6.03%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-6.93%
We cut SG&A while MCHP invests at 2.69%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.